PA
SGHC icon

PharVision Advisers’s SGHC Ltd SGHC Stock Holding History

PharVision Advisers’s Portfolio SGHC Stock Details SGHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,598
Closed -$473K – 557
2025
Q4 		$473K Buy
39,598
+27,568
+229% +$331K 0.24% 53
2025
Q3 		$159K Buy
+12,030
New +$142K 0.09% 559
2025
Q2 		– Sell
-11,044
Closed -$71.1K – 413
2025
Q1 		$71.1K Buy
+11,044
New +$79.3K 0.1% 257

Other funds holding SGHC

DSCM
Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's SGHC Position: Q1 2026 in Review

PharVision Advisers sold out of SGHC Ltd (SGHC) in Q1 2026, closing a stake of 39,598 shares — an estimated $473K sold.

PharVision Advisers first reported a position in SGHC in Q1 2025 and held it in 3 quarters. The position peaked at $473K in Q4 2025. 199 funds tracked by Wall St. Rank hold SGHC as of Q1 2026.

  • PharVision Advisers reported no remaining SGHC Ltd position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 39,598 SGHC Ltd shares in Q1 2026, an estimated $473K.
  • PharVision Advisers first reported a position in SGHC Ltd in Q1 2025 and held it in 3 quarters.
  • PharVision Advisers's SGHC Ltd position peaked at $473K in Q4 2025.
  • 199 funds tracked by Wall St. Rank held SGHC Ltd as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.